Navigation Links
CeNeRx Initiates Phase II Trial of TriRima™ as Monotherapy in Treatment Resistant Depression
Date:1/6/2011

RESEARCH TRIANGLE PARK, N.C., Jan. 6, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., today reported that it has initiated a Phase II trial of its new formulation of TriRima™, the company's novel antidepressant in development as monotherapy for treatment resistant depression.  CeNeRx also announced that it will be presenting at Biotech Showcase™ 2011 on Tuesday, January 11, 2011 at 11:00 AM PST.

TriRima is a member of a novel class of drugs known as RIMAs, or reversible and selective inhibitors of monoamine oxidase A (MAO-A).  MAO inhibitors achieve superior "triple-action" antidepressant efficacy by elevating the levels of all three of the key neurotransmitters that positively affect mood.  However, older MAO inhibitors have been limited by their potential to cause serious cardiovascular side effects when foods containing the naturally occurring substance tyramine are consumed.  

TriRima is designed to achieve the efficacy of the MAO inhibitor class while reducing or eliminating the risk of these food-associated effects.  In a recently reported "tyramine challenge" study, subjects receiving the new formulation of TriRima showed no signs of any negative effects, even after being exposed to large amounts of tyramine.  These positive results further confirmed the good safety profile demonstrated by TriRima in Phase I studies.

The Phase II trial is a double blind, placebo-controlled study designed to assess the efficacy of TriRima administered twice daily as monotherapy in patients with treatment resistant depression.  Secondary objectives include evaluating TriRima's safety and tolerability and assessing its pharmacokinetic profile.  CeNeRx expects to enroll 360 patients in the study, which is being conducted at multiple centers in the U.S.

"We are eager to test the efficacy of our promising new formulation of TriRima
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
5. CeNeRx BioPharma Completes $13 Million Series C Financing
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015  Today, in final recognition of the ... Health Week, 1-800 Contacts is sharing how to keep ... lens wearers who do not properly care for their ... infections. Most contact lens wearers understand ... clean lens case is sometimes overlooked.  When proper steps ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by AstraZeneca plc, quetiapine ... important drug for the treatment of schizophrenia. Approved ... was listed in the Catalogue of Drugs for ...
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Quetiapine Market Investigation Report 2010-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... the novel,selective relaxant binding agent (SRBA) being developed ... neuromuscular blockade as,compared to neostigmine in the Phase ... Spectrum, faster recovery from profound neuromuscular,blockade compared to ... were presented today at the 2007 annual meeting ...
... safety of nebulized,formoterol fumarate and safety/ efficacy of concomitant use with ... ... 16 Dey, L.P., a subsidiary of Mylan,Inc. (NYSE: MYL ... the annual scientific assembly of the American College of,Chest Physicians (ACCP) ...
Cached Medicine Technology:Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 2Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 3Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 4Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 5Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 2Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 3Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 4Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007 5
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... Houston, TX (PRWEB) , ... August 29, 2015 ... ... settlement allows the company to freely market and sell Arterosil and Arterosil HP, ... Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the ...
(Date:8/28/2015)... Richey, FL (PRWEB) , ... August 28, 2015 , ... ... many potential workers are qualified for the position they are applying for, they are ... of this, many employers are considering altering drug testing policies in order to be ...
(Date:8/28/2015)... Baltimore, MD (PRWEB) , ... August 28, 2015 , ... ... reduction system from Merz, received FDA clearance for results that last for two ... clearance is exciting news for patients who are looking for a long-lasting, effective solution ...
(Date:8/28/2015)... , ... August 28, 2015 , ... “ Frequentz ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers how this software allows businesses to track product movement from beginning ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... ... ... Hayes, Inc., the nation’s leading health technology research and consulting company, today announced that ... has joined the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC). The MEDCAC ...
... is not a replacement for HIV-specific drugs, researchers say , ... people who are infected with both HIV-1, a strain of ... benefit in more than one way by taking a herpes ... appears to also slow the progression of HIV. , ...
... , , , , , , ... ( SVA),a leading China -based vaccine manufacturer, today announced the ... land use,rights. The total consideration for the purchase is approximately ... working capital. The,initial payment of RMB56.5 million ( $8.3 ...
... ... covers annual dental cleanings , ... Canton, OH (PRWEB) February 15, 2010 -- Preventive care can serve as the best protection ... Pet Health Insurance makes this care even easier for pet parents to afford., , ,About ...
... , ... lawyers scrutinize the defect which causes Toyota made cars and trucks to accelerate when the ... ... of almost 2.3 million vehicles on January 21, because the company learned that accelerator pads ...
... ... CO2 fire extinguishers and extinguishers with frost-free horns. , ... Dartford, Kent (PRWEB) February 15, 2010 -- Fire ... fire extinguishers actually pose some safety hazards of their own: If incorrectly handled ...
Cached Medicine News:Health News:Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 2Health News:Sinovac Completes Acquisition Aimed at Expanding Production Capacity 3Health News:Pet Dental Month Prime Time To Schedule Preventive Annual Cleaning For Pets 2Health News:Toyota Recalls Millions of Defective Vehicles 2Health News:Toyota Recalls Millions of Defective Vehicles 3Health News:Fire Protection Online Resolves Safety Concerns with CO2 Fire Extinguishers 2
... for eyecare professionals- Winx Pro ... practice management system, using the ... Pro is a complete solution ... effectively managing the administrative, financial ...
The Advia 60 is designed to deliver powerful performance in a small package....
The XT-2000i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
Ac.T 5diff CP allows quick and direct access to a closed sample tubea feature that reduces manual sample handling, saves time and enhances safety by eliminating operators exposure to biohazards....
Medicine Products: